凯赛生物公告，2024年营业收入29.58亿元，同比增长39.91%。归属于上市公司股东的净利润4.89亿 元，同比增长33.41%。拟向全体股东每10股派发现金红利4元(含税)。 ...

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities synthetic biology index, which includes 58 companies across various sectors, has seen a decline of 9.66% recently, underperforming compared to the Shanghai Composite Index [5][17] Industry Market Dynamics - The synthetic biology sector's stocks have performed poorly recently, with a 9.66% drop, ranking 32nd among sectors [17] - The top five gainers in the synthetic biology sector include: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxiang Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The top five losers include: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yabao Chemical (-9%) - Berry Genomics (-7%) - Weilan Bio (-6%) [22] Company Business Developments - Anhui Pucan has launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate its polyurethane supply chain, with projected revenues exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] - Kosemet announced a partnership with Shanghai Xinhai Biotechnology to develop bio-synthesized retinol for skincare products [25] Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [28] - Zhongsheng Suyuan Biotechnology completed a B round financing of 235 million yuan, focusing on iPSC-derived cell therapies [28] - Korean company INTAKE raised approximately 9.2 million USD in a C round financing to develop precision fermentation proteins [29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom protein received FDA GRAS certification, allowing it to enter the U.S. market [31] - MycoTechnology's truffle sweet protein product received FEMA GRAS certification, showcasing advancements in natural flavoring solutions [32] - Nourish Ingredients and Cabio Biotech successfully commercialized a precision fermentation fat product, enhancing the flavor of plant-based products [34]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global revolution, integrating into economic and social development to address major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [4] Industry Market Dynamics - The synthetic biology index decreased by 9.66% to 1437.31 during the week of April 5-11, 2025, underperforming compared to the Shanghai Composite Index, which fell by 1.62%, and the ChiNext Index, which dropped by 4.21% [5][17] - The top five performing companies in the synthetic biology sector during this period were: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxing Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The bottom five performing companies were: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yaborn Chemical (-9%) - Berry Genomics (-7%) - Blue Biological (-6%) [22] Company Business Developments - Anhui Pucan launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate the polyurethane supply chain, with projected combined revenue exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly 100 firms completing new rounds of funding since the beginning of 2025. Zhongsheng Suyuan Biotechnology raised 235 million yuan in its B round, focusing on iPSC-derived cell therapies [28][29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom mycelium protein received FDA GRAS certification, allowing entry into the U.S. market [31] - MycoTechnology's truffle sweet protein ClearHT received FEMA GRAS certification, showcasing advancements in natural flavoring and health foods [32]

上海凯赛生物技术股份有限公司 章 程 2025 年 4 月 | 第一章 总则 2 | | | --- | --- | | 第二章 经营宗旨和经营范围 3 | | | 第三章 股份 3 | | | 第一节 股份发行 3 | | | 第二节 股份增减和回购 5 | | | 第三节 股份转让 6 | | | 第四章 股东和股东大会 7 | | | 第一节 股东 7 | | | 第二节 股东大会的一般规定 9 | | | 第三节 股东大会的召集 13 | | | 第四节 股东大会的提案与通知 14 | | | 第五节 股东大会的召开 15 | | | 第六节 股东大会的表决和决议 18 | | | 第五章 董事会 24 | | | 第一节 董事 24 | | | 第二节 董事会 26 | | | 第六章 总裁及其他高级管理人员 | 30 | | 第七章 监事会 32 | | | 第一节 监事 32 | | | 第二节 监事会 33 | | | 第八章 财务会计制度、利润分配和审计 34 | | | 第一节 财务会计制度 34 | | | 第二节 内部审计 37 | | | 第三节 会计师事务所的聘任 38 | | | ...

关于变更公司注册资本、修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海凯赛生物技术股份有限公司 证券代码：688065 证券简称：凯赛生物 公告编号：2025-017 上海凯赛生物技术股份有限公司（以下简称 "公司"）于 2025 年 4 月 14 日召 开的第二届董事会第二十九次会议，审议通过了《关于变更公司注册资本、修订<公 司章程>的议案》，具体情况如下： 一、 公司注册资本变更情况 2024 年 12 月 3 日，公司收到中国证监会出具的《关于同意上海凯赛生物技术 股份有限公司向特定对象发行股票注册的批复》（证监许可〔2024〕1662号）（注 册生效日期为 2024 年 11 月 25 日），同意公司向特定对象发行股票的注册申请， 有效期为 12 个月。 本次发行新增股份 137,911,755 股已于 2025 年 3 月 31 日在中国证券登记结算 有限责任公司上海分公司办理完毕股份登记手续。因公司定向增发 A 股股票完成， 公司注册资本由人民币 583,378,039 元变更为人 ...

上海凯赛生物技术股份有限公司 董 事 会 2025 年 4 月 1 5 日 证券代码：688065 证券简称：凯赛生物 公告编号：2025-015 上海凯赛生物技术股份有限公司 关于聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 14 日召 开第二届董事会第二十九次会议，审议并通过了《关于聘任公司副总裁的议案》 《关于聘任公司财务总监的议案》，同意聘任曾原先生为公司副总裁（曾原先生简 历详见附件），同意聘任杨文颖女士为公司财务总监（杨文颖女士简历详见附件）， 任期自本次董事会审议通过之日起至第二届董事会任期届满之日止。 本次董事会聘任曾原先生为公司副总裁事项已经过提名委员会审议通过，聘任 杨文颖女士为公司财务总监的事项已经过审计委员会、提名委员会审议通过。提名、 聘任程序及表决结果均符合法律、法规及《公司章程》的有关规定。 特此公告。 杨文颖女士简历 杨文颖女士，1989 年 12 月出生，中国国籍，无境外居留权，管理学学士。 ...

关于选举非独立董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 14 日召 开第二届董事会第二十九次会议，审议并通过了《关于补充选举第二届董事会非独 立董事的议案》。具体内容如下： 为完善公司治理结构，保证公司董事会的规范运作，根据《公司法》《公司章 程》等相关规定，经董事会提名委员会审查，董事会同意提名邓伟栋先生、卢奕扬 先生为公司第二届董事会非独立董事候选人（邓伟栋先生、卢奕扬先生简历详见附 件），任期与第二届董事会任期一致。《关于补充选举第二届董事会非独立董事的 议案》尚需提交公司股东大会审议。 证券代码：688065 证券简称：凯赛生物 公告编号：2025-016 上海凯赛生物技术股份有限公司 上海凯赛生物技术股份有限公司 卢奕扬先生简历 邓伟栋先生简历 邓伟栋先生，1967 年 7 月出生，中国国籍，无境外居留权，博士研究生。曾任 职海南省洋浦经济开发区管理局、中国南山集团、深圳赤湾港航股份有限公司，后 历任招商局国际有限公司副总 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-018 （一） 股东大会类型和届次 2025 年第一次临时股东大会 召开日期时间：2025 年 5 月 16 日 14 点 00 分 召开地点：上海市闵行区绿洲环路 396 弄 11 号 9 楼会议室 上海凯赛生物技术股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 5 月 16 日 至 2025 年 5 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年5月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期 ...

Core Viewpoint - Shanghai Cathay Biotech Co., Ltd. is conducting a private placement of A-shares, which will significantly increase the control of its major shareholder, Shanghai Yaoxiu, from 20.00% to 35.29% after the issuance, thereby consolidating the actual control of the company by Xiucai Liu's family [2][20]. Group 1: Issuance Details - The total number of shares to be issued is 137,911,755, which does not exceed 30% of the total share capital before the issuance [12][19]. - The issuance price is set at 42.97 CNY per share, adjusted from an initial price of 43.34 CNY due to previous dividend distributions [14][13]. - The total funds raised from this issuance amount to 5,926,068,112.35 CNY, with a net amount of 5,914,724,993.63 CNY after deducting issuance costs [12][26]. Group 2: Shareholder Structure - Post-issuance, the actual control of the company by Xiucai Liu's family and controlled enterprises will increase to 44.04% [20]. - The major shareholder, Shanghai Yaoxiu, will have its shareholding increased significantly, enhancing its control over the company [2][20]. - The shareholding structure complies with the listing conditions as per the relevant regulations [2][20]. Group 3: Lock-up Period and Trading - The shares issued will be subject to a lock-up period of 60 months, during which they cannot be transferred [15][27]. - After the lock-up period, the shares will be listed and traded on the Shanghai Stock Exchange's Sci-Tech Innovation Board [27]. Group 4: Company Overview - Shanghai Cathay Biotech Co., Ltd. specializes in the research, production, and sales of new bio-based materials, primarily focusing on bio-based long-chain dicarboxylic acids and bio-based polyamide products [6][7]. - The company has established long-term partnerships with international firms such as DuPont and Evonik, leveraging its leading position in the global market for bio-based long-chain dicarboxylic acids [7][20].

Core Viewpoint - Shanghai Kasei Biotechnology Co., Ltd. has completed the issuance of A-shares to a specific entity, Shanghai Yaoxiu Biotechnology Partnership, raising approximately RMB 5.93 billion through the issuance of 137,911,755 shares at a price of RMB 42.97 per share [1][2][3] Summary by Sections Issuance Details - The company issued 137,911,755 A-shares at a par value of RMB 1.00 per share, with a total subscription amount of RMB 5,926,068,112.35 [1][3] - The issuance has been registered and completed with the China Securities Depository and Clearing Corporation [1][3] Control and Ownership Changes - The actual controller of the company remains the Liu Xiucai family, despite the change in the controlling shareholder from CIB to Shanghai Yaoxiu [2][6][8] - Before the issuance, CIB held 28.32% of the shares, which will decrease to 6.73% post-issuance, while Shanghai Yaoxiu will hold 35.29% [4][6][8] - The Liu Xiucai family controlled a total of 30.82% of the voting rights before the issuance, which will increase to 44.04% after the issuance [6][8] Regulatory Approvals - The issuance plan has been approved by multiple board meetings and shareholder meetings, ensuring compliance with relevant regulations [2][3] - The registration approval for the issuance is valid for 12 months, expiring on November 25, 2024 [3][5] Transaction Completion - The share transfer from CIB to Shanghai Yaoxiu, involving 116,655,640 shares, has been completed, with the transfer date recorded as December 31, 2024 [7][8] - The company has disclosed the completion of the share transfer and the change in controlling shareholder on January 3, 2025 [7][8]